The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China
ObjectiveThis study aims to analyze the serotype distribution and drug resistance of Streptococcus pneumoniae isolated from children aged 8 days to 7 years in Urumqi, China, between 2014 to 2021, during which PCV13 was introduced in the private sector’s immunization program and COVID-19 control was...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1110652/full |
| _version_ | 1811166841718964224 |
|---|---|
| author | Meng-Yang Guo Xing-Hai Shi Wei Gao Ju-Ling Tian Lin Yuan Juan Yang Dilinuer Wumaier Jiang Cao Reziwaguli Abulimiti Wen-Li Zhang Kai-Hu Yao |
| author_facet | Meng-Yang Guo Xing-Hai Shi Wei Gao Ju-Ling Tian Lin Yuan Juan Yang Dilinuer Wumaier Jiang Cao Reziwaguli Abulimiti Wen-Li Zhang Kai-Hu Yao |
| author_sort | Meng-Yang Guo |
| collection | DOAJ |
| description | ObjectiveThis study aims to analyze the serotype distribution and drug resistance of Streptococcus pneumoniae isolated from children aged 8 days to 7 years in Urumqi, China, between 2014 to 2021, during which PCV13 was introduced in the private sector’s immunization program and COVID-19 control was administrated in the last 2 years.MethodsSerotypes of S. pneumoniae isolates were determined by Quellung reaction, and their susceptibility against 14 antimicrobials were tested. According to the start year of PCV13 administration (2017) and COVID-19 control (2020), the study period was divided into three stages: 2014–2015, 2018–2019, and 2020–2021.ResultsA total of 317 isolates were involved in this study. The most common serotypes were type 19F (34.4%), followed by 19A (15.8%), 23F (11.7%), 6B (11.4%), and 6A(5.0%). The coverage rate of both PCV13 and PCV15 was 83.0%. The coverage of PCV20 was a little higher at 85.2%. The resistance rate against penicillin was 28.6% according to the breakpoints of oral penicillin, which would reach up to 91.8% based on the breakpoints of parenteral penicillin for meningitis. The resistance rates to erythromycin, clindamycin, tetracycline, and sulfamethoxazole-trimethoprim were 95.9%, 90.2%, 88.9%, and 78.8%, respectively. The PCV13 isolate was more resistant to penicillin than the non-PCV13 ones. There was not any significant change found in the serotype distribution since the PCV13 introduction and the COVID-19 control. The resistance rate against oral penicillin slightly elevated to 34.5% in 2018–2019 from 30.7% in 2014–2015 and then decreased significantly to 18.1% in 2020–2021 (χ2 = 7.716, P < 0.05), while the resistance rate to ceftriaxone (non-meningitis) continuously declined from 16.0% in 2014–2015 to 1.4% in 2018–2019 and 0% in 2020–2021 (Fisher = 24.463, P < 0.01).ConclusionThe common serotypes of S. pneumoniae isolated from children in Urumqi were types 19F, 19A, 23F, 6B, and 6A, which we found to have no marked change since the PCV13 introduction and the COVID-19 control However, the resistance rate to oral penicillin and ceftriaxone significantly declined in the COVID-19 control stage. |
| first_indexed | 2024-04-10T16:00:03Z |
| format | Article |
| id | doaj.art-270345673949467db6a2f2b74a9be65b |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-04-10T16:00:03Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-270345673949467db6a2f2b74a9be65b2023-02-10T13:58:48ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882023-01-011310.3389/fcimb.2023.11106521110652The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, ChinaMeng-Yang Guo0Xing-Hai Shi1Wei Gao2Ju-Ling Tian3Lin Yuan4Juan Yang5Dilinuer Wumaier6Jiang Cao7Reziwaguli Abulimiti8Wen-Li Zhang9Kai-Hu Yao10Ministry of Education (MOE) Key Laboratory of Major Diseases in Children, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, ChinaMedical Laboratory, Urumqi Children’s Hospital, Beijing, ChinaMinistry of Education (MOE) Key Laboratory of Major Diseases in Children, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, ChinaMedical Laboratory, Urumqi Children’s Hospital, Beijing, ChinaMinistry of Education (MOE) Key Laboratory of Major Diseases in Children, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, ChinaMedical Laboratory, Urumqi Children’s Hospital, Beijing, ChinaMedical Laboratory, Urumqi Children’s Hospital, Beijing, ChinaMedical Laboratory, Urumqi Children’s Hospital, Beijing, ChinaMedical Laboratory, Urumqi Children’s Hospital, Beijing, ChinaMedical Laboratory, Urumqi Children’s Hospital, Beijing, ChinaMinistry of Education (MOE) Key Laboratory of Major Diseases in Children, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, ChinaObjectiveThis study aims to analyze the serotype distribution and drug resistance of Streptococcus pneumoniae isolated from children aged 8 days to 7 years in Urumqi, China, between 2014 to 2021, during which PCV13 was introduced in the private sector’s immunization program and COVID-19 control was administrated in the last 2 years.MethodsSerotypes of S. pneumoniae isolates were determined by Quellung reaction, and their susceptibility against 14 antimicrobials were tested. According to the start year of PCV13 administration (2017) and COVID-19 control (2020), the study period was divided into three stages: 2014–2015, 2018–2019, and 2020–2021.ResultsA total of 317 isolates were involved in this study. The most common serotypes were type 19F (34.4%), followed by 19A (15.8%), 23F (11.7%), 6B (11.4%), and 6A(5.0%). The coverage rate of both PCV13 and PCV15 was 83.0%. The coverage of PCV20 was a little higher at 85.2%. The resistance rate against penicillin was 28.6% according to the breakpoints of oral penicillin, which would reach up to 91.8% based on the breakpoints of parenteral penicillin for meningitis. The resistance rates to erythromycin, clindamycin, tetracycline, and sulfamethoxazole-trimethoprim were 95.9%, 90.2%, 88.9%, and 78.8%, respectively. The PCV13 isolate was more resistant to penicillin than the non-PCV13 ones. There was not any significant change found in the serotype distribution since the PCV13 introduction and the COVID-19 control. The resistance rate against oral penicillin slightly elevated to 34.5% in 2018–2019 from 30.7% in 2014–2015 and then decreased significantly to 18.1% in 2020–2021 (χ2 = 7.716, P < 0.05), while the resistance rate to ceftriaxone (non-meningitis) continuously declined from 16.0% in 2014–2015 to 1.4% in 2018–2019 and 0% in 2020–2021 (Fisher = 24.463, P < 0.01).ConclusionThe common serotypes of S. pneumoniae isolated from children in Urumqi were types 19F, 19A, 23F, 6B, and 6A, which we found to have no marked change since the PCV13 introduction and the COVID-19 control However, the resistance rate to oral penicillin and ceftriaxone significantly declined in the COVID-19 control stage.https://www.frontiersin.org/articles/10.3389/fcimb.2023.1110652/fullStreptococcus pneumoniaeserotypedrug resistancechildrenCOVID-19 |
| spellingShingle | Meng-Yang Guo Xing-Hai Shi Wei Gao Ju-Ling Tian Lin Yuan Juan Yang Dilinuer Wumaier Jiang Cao Reziwaguli Abulimiti Wen-Li Zhang Kai-Hu Yao The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China Frontiers in Cellular and Infection Microbiology Streptococcus pneumoniae serotype drug resistance children COVID-19 |
| title | The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China |
| title_full | The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China |
| title_fullStr | The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China |
| title_full_unstemmed | The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China |
| title_short | The dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China |
| title_sort | dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since pcv13 administration and covid 19 control in urumqi china |
| topic | Streptococcus pneumoniae serotype drug resistance children COVID-19 |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1110652/full |
| work_keys_str_mv | AT mengyangguo thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT xinghaishi thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT weigao thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT julingtian thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT linyuan thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT juanyang thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT dilinuerwumaier thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT jiangcao thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT reziwaguliabulimiti thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT wenlizhang thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT kaihuyao thedynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT mengyangguo dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT xinghaishi dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT weigao dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT julingtian dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT linyuan dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT juanyang dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT dilinuerwumaier dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT jiangcao dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT reziwaguliabulimiti dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT wenlizhang dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina AT kaihuyao dynamicchangeofserotypedistributionandantimicrobialresistanceofpneumococcalisolatessincepcv13administrationandcovid19controlinurumqichina |